The latest updated of drug registration lists on 07 July 2025.

Close

No Brand Name Ingredients Dosage Form Primary Packaging Indications EDL License Owner Manufacturer Country Activity Reg No. Reg Date Expiry Date Action
461 CRYSTORVAS TABLET 20 MG ATORVASTATIN CALCIUM TRIHYDRATE( CRYSTALLINE) 22.20 MG EQ.TO ATORVASTATIN 20 MG FILM COATED TABLET ALU-ALU PVC BLISTER AS AN ADJUNCT TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED TOTAL CHOLESTEROL, LDL-CHOLESTEROL, APOLIPOPROTEIN B AND TRIGLYCERIDES AND TO INCREASE HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, COMBINED HYPERLIPIDEMIA (FREDRICKSON TYPES IIA AND IIB), ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDRICKSON TYPE IV) AND FOR PATIENTS WITH DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET NULL DKSH LAOS COMPANY LIMITED DUOPHARMA MANUFACTURING(BANGI)SDN.BHD. MALAYSIA CERTIFICATE RELEASED 05 I 5513/23 15-MAY-2023 14-MAY-2026 View
462 CRYSTORVAS TABLET 40 MG ATORVASTATIN CALCIUM TRIHYDRATE( CRYSTALLINE) 44.40 MG EQ.TO ATORVASTATIN 40 MG FILM COATED TABLET ALU-ALU PVC BLISTER AS AN ADJUNCT TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED TOTAL CHOLESTEROL, LDL-CHOLESTEROL, APOLIPOPROTEIN B AND TRIGLYCERIDES AND TO INCREASE HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, COMBINED HYPERLIPIDEMIA (FREDRICKSON TYPES IIA AND IIB), ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDRICKSON TYPE IV) AND FOR PATIENTS WITH DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET NULL DKSH LAOS COMPANY LIMITED DUOPHARMA MANUFACTURING(BANGI)SDN.BHD. MALAYSIA CERTIFICATE RELEASED 05 I 5514/23 15-MAY-2023 14-MAY-2026 View
463 CYPRESS CYPROTERONE ACETATE PH.EUR 2 MG, ETHINYLESTRADIOL PH.EUR 0.035 MG FILM COATED TABLET ALU/PVDC TREATMENT OF MODERATE TO SEVERE ACNE RELATED TO ANDROGEN-SENSITIVITY (WITH OR WITHOUT SEBORRHOEA) AND/OR HIRSUTISM, IN WOMEN OF REPRODUCTIVE AGE. FOR THE TREATMENT OF ACNE, CYPRESS SHOULD ONLY BE USED AFTER THERAPY OR SYSTEMIC ANTIBIOTIC TREATMENTS HAVE FAILED NULL DKSH LAOS COMPANY LIMITED MYLAN LABORATORIES LIMITED INDIA CERTIFICATE RELEASED 01 I 5665/24 26-JAN-2024 25-JAN-2027 View
464 DAISY P DESOGESTREL PH.EUR 150 MCG, ETHINYLESTRADIOL PH.EUR 30 MCG TABLET ALU-PVC/PVDC ORAL CONTRACEPTION NULL DKSH LAOS COMPANY LIMITED MYLAN LABORATORIES LIMITED INDIA CERTIFICATE RELEASED 05 I 5515/23 15-MAY-2023 14-MAY-2026 View
465 DEMOTHINE INJECTION 100 MG/ 2 ML PETHIDINE HYDROCHLORIDE 100 MG/ 2 ML SOLUTION FOR INJECTION AMPOULES FOR RELIEF OF MODERATE TO SEVERE PAIN NOT RESPONSIVE TO NOB-NARCOTIC ANALGESICS. IT MAY ALSO BE USED AS PRE-OPERATIVE MEDICATION AND AS AN ANALGESIC ADJUNCT IN GENERAL ANAESTHESIA AND TO PROVIDE OBSTETRICAL ANALGESIA NULL DKSH LAOS COMPANY LIMITED DUOPHARMA (M) SDN BHD MALAYSIA CERTIFICATE RELEASED 06 I 5541/23 26-Jun-2023 25-Jun-2026 View
466 DEPO-PROVERA MEDROXYPROGESTERONE ACETATE 150 MG/ML SUSPENSION FOR INJECTION VIAL FOR LONG - TERM FEMALE CONTRACEPTION, DEPO-PROVERA IS SUITABLE FOR USE IN WOMEN WHO HAVE BEEN APPROPRIATELY CONSELLED CONCERNING THE LIKELIHOOD OF MENSTRUAL DISTURBANCE AND THE POTENTIAL FOR A DELAY IN RETURN TO FULL FERTILITY. NULL DKSH LAOS COMPANY LIMITED PFIZER MANUFACTURING BELGIUM NV BELGIUM CERTIFICATE RELEASED 07 I 5256/22 17-Aug-2022 16-Aug-2025 View
467 DILANTIN (INFATAB) PHENYTOIN 50 MG TABLET BOTTLE PHENYTOIN IS INDICATED FOR THE CONTROL OF GENERALIZED TONIC-CLONIC ( GRAND MAL) AND COMPLEX PARTIAL (PSYCHOMOTOR, TEMPORAL LOBE) SEIZURES AND PREVENTION AND TREATMENT OF SEIZURES OCCURRING DURING OR FOLLOWING NEUROSURGERY. NULL DKSH LAOS COMPANY LIMITED OLIC (THAILAND) LIMITED THAILAND CERTIFICATE RELEASED 11 I 3996/13 25-SEP-2024 24-SEP-2029 View
468 DIMPLE MEDROXYPROGESTERONE ACETATE USP 150MG/ML SUSPENSION FOR INJECTION VIAL SUPPRESSION OF OVULATION(CONTRACEPTION), SINCE LOSS OF BONE MINERAL DENSITY MAY OCCUR IN PRE MENOPAUSAL WOMEN WHO USE MEDROXYPROGESTERONE ACTETATE INJECTIONS LONG TERM, A RISK/BENEFIT ASSESSMENT, WHICH ALSO TAKES INTO CONSIDERATION THE DECREASE IN BONE MINERAL DENSITY THAT OCCURS DURING PREGNANCY AND/OR LACTATION, SHOULD BE CONSIDERED NULL DKSH LAOS COMPANY LIMITED MYLAN LABORATORIES LIMITED INDIA CERTIFICATE RELEASED 01 I 5182/22 07-APR-2025 06-APR-2030 View
469 DYMISTA AZELASTINE HYDROCHLORIDE 137 MCG, FLUTICASONE PROPIONATE 50 MCG NASAL SPRAY BOTTLE RELIEF OF SYMPTOMS OF MODERATELY SEVERE TO SEVERE SEASONAL AND PARENNIAL ALLERGIC RHINITIS IF MONOTHERAPY WITH EITHER INTRANASAL ANTIHISTAMINE OR GLUCOCORTICOID IS NOT CONSIDERED SUFFICIENT NULL DKSH LAOS COMPANY LIMITED CIPLA LIMITED GERMANY CERTIFICATE RELEASED 04 I 5478/23 25-APR-2023 24-APR-2026 View
470 DYNAPAR GEL OLEUM LINI (LINSEED OIL BP) CONTAINING PREDOMINANTLY ALPHA LINOLENIC ACID) 3 % W/W, DICLOFENAC DIETHYLAMINE BP 1.16 % W/W EQ.TO DICLOFENAC SODIUM 1 %W/W, METHYL SALICYLATE BP 10 % W/W, MENTHOL USP 5 %W/W. GEL TUBE FOR THE LOCAL SYMPTOMATIC RELIEF OF PAIN AND INFLAMMATION IN TRAUMA OF THE TENDONS, LIGAMENTS, MUSCLES AND JOINTS. LOCALISED FORMS OF SOFT TISSUE RHEUMATISM, IT IS RECOMMENDED THAT TREATMENT BE REVIEWED AFTER 14 DAYS IN THESE INDICATIONS. FOR THE TREATMENT OF OSTEOARTHRITIS OF SUPERFICIAL JOINTS SUCH AS THE KNEE, IN THE TREATMENT OF OSTEOARTHRITIS, THERAPY SHOULD BE REVIEW AFTER 4 WEEKS NULL DKSH LAOS COMPANY LIMITED TROIKAA PHARMACEUTICALS LIMITED INDIA CERTIFICATE RELEASED 05 I 5093/21 08-APR-2024 07-APR-2027 View
 
© 2014 ສະຫງວນລິຂະສິດໂດຍ ກົມອາຫານ ແລະ ຢາ, ກະຊວງສາທາລະນະສຸກ, ສປປລາວ.
ຕິດຕໍ່ ກອຢ      ອີເມວ      ເຂົ້າລະບົບ